8-K current report · filed Nov 5, 2026

PALVELLA THERAPEUTICS, INC. (PVLA) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2PVLA overview

Short answer

PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Fiscal-quarter results announced for period ended September 30, 2026.

PALVELLA THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal-quarter results announced for period ended September 30, 2026
  • Full financial details and management commentary contained in Exhibit 99.1 press release
  • Results announcement provides investors an update on Palvella’s financial condition and operating performance

Item 7.01 · Regulation FD Disclosure

  • Earnings call scheduled for November 5, 2026, covering the company’s fiscal 2026 results
  • Investor presentation furnished as Exhibit 99.2, likely providing supplemental operating and financial commentary

Item EX-99.1 · Exhibit EX-99.1

  • FDA accepted QTORIN rapamycin’s NDA for microcystic lymphatic malformations, with Priority Review and February 28, 2027 PDUFA target
  • Potential first FDA-approved therapy for a disease affecting more than 30,000 diagnosed U.S. children and adults
  • Standalone U.S. launch preparations underway for first half of 2027, contingent on approval
  • Cash, equivalents and short-term investments $236.7M at September 30, 2026, supporting launch preparation and pipeline expansion
  • Q3 net loss $24.6M, or $1.70 per share, versus $11.3M, or $1.03 per share, in Q3 2025

Item EX-99.2 · Exhibit EX-99.2

  • QTORIN rapamycin NDA accepted with Priority Review, with FDA action targeted for February 28, 2027
  • Potential standalone U.S. launch in 1H 2027 for microcystic lymphatic malformations, an estimated >30,000 diagnosed patients
  • Commercial readiness advancing: >70 field-based employees planned and >70% of surveyed physicians intend to prescribe within 3 months
  • Cash, cash equivalents and short-term investments totaled $236.7 million at September 30, 2026, supporting launch and pipeline development
  • Pipeline expansion includes cutaneous venous malformations, angiokeratomas and DSAP, with multiple Phase 2 or Phase 3 milestones expected through 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PALVELLA THERAPEUTICS, INC. 8-K filings

Get the next PVLA 8-K as it lands

Follow PVLA for push alerts, or ask the research agent what this filing means.